BACKGROUND: Real-life data on long-term effectiveness and safety of dupilumab in atopic dermatitis patients is limited. OBJECTIVE: To study 52-weeks effectiveness and safety of dupilumab in a prospective multi-center cohort of adult patients with treatment-refractory atopic dermatitis. METHODS: Patients treated with dupilumab participating in the Dutch BioDay-registry were included. Clinical effectiveness and safety were evaluated. RESULTS: 210 atopic dermatitis patients were included. Mean percent change in EASI after 16 weeks was -70.0% (SD 33.2) and further decreased to -76.6% (SD 30.6) by week 52. EASI-75 was achieved by 59.9% at week 16 and 70.3% at week 52. The most reported side effect was conjunctivitis (34%). Limited patients (17 (8.1%))discontinued dupilumab treatment. LIMITATIONS: Due to the lack of a control-group and observational design, factors of bias may have been induced. CONCLUSION: Treatment with dupilumab resulted in a rapid improvement in clinical outcome measures, and effectiveness further improved during the 52-week follow-up period.
BACKGROUND: Real-life data on long-term effectiveness and safety of dupilumab in atopic dermatitispatients is limited. OBJECTIVE: To study 52-weeks effectiveness and safety of dupilumab in a prospective multi-center cohort of adult patients with treatment-refractory atopic dermatitis. METHODS:Patients treated with dupilumab participating in the Dutch BioDay-registry were included. Clinical effectiveness and safety were evaluated. RESULTS: 210 atopic dermatitispatients were included. Mean percent change in EASI after 16 weeks was -70.0% (SD 33.2) and further decreased to -76.6% (SD 30.6) by week 52. EASI-75 was achieved by 59.9% at week 16 and 70.3% at week 52. The most reported side effect was conjunctivitis (34%). Limited patients (17 (8.1%))discontinued dupilumab treatment. LIMITATIONS: Due to the lack of a control-group and observational design, factors of bias may have been induced. CONCLUSION: Treatment with dupilumab resulted in a rapid improvement in clinical outcome measures, and effectiveness further improved during the 52-week follow-up period.
Authors: Lieneke F M Ariëns; Daphne S Bakker; Lotte S Spekhorst; Jorien Van der Schaft; Judith L Thijs; Inge Haeck; Annebeth E Flinterman; Marijke Kamsteeg; Marie L A Schuttelaar; Marjolein S De Bruin-Weller Journal: Acta Derm Venereol Date: 2021-10-19 Impact factor: 3.875
Authors: Jonathan I Silverberg; Eric L Simpson; Mark Boguniewicz; Marjolein S De Bruin-Weller; Peter Foley; Yoko Kataoka; Gaëlle Bégo-Le-Bagousse; Zhen Chen; Brad Shumel; Jingdong Chao; Ana B Rossi Journal: Acta Derm Venereol Date: 2021-11-10 Impact factor: 3.875
Authors: Ricardo Ruiz-Villaverde; Javier Domínguez-Cruz; Francisco J Navarro-Triviño; Manuel Galán-Gutiérrez; Jose Carlos Armario-Hita; Jose Juan Pereyra-Rodriguez Journal: Life (Basel) Date: 2022-08-04